2023
Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders
Baglaenko Y, Wagner C, Bhoj V, Brodin P, Gershwin M, Graham D, Invernizzi P, Kidd K, Korsunsky I, Levy M, Mammen A, Nizet V, Ramirez-Valle F, Stites E, Williams M, Wilson M, Rose N, Ladd V, Sirota M. Making inroads to precision medicine for the treatment of autoimmune diseases: Harnessing genomic studies to better diagnose and treat complex disorders. Cambridge Prisms Precision Medicine 2023, 1: e25. PMID: 38550937, PMCID: PMC10953750, DOI: 10.1017/pcm.2023.14.Peer-Reviewed Original ResearchAutoimmune diseasesPrecision medicinePathogenic autoantigenPatient subtypesDisease heterogeneityComplex etiologyMolecular profilingDiseaseAccount individual variabilityDisease mechanismsForeign cellsMolecular pathwaysNatural defense systemComplex disorderDisease treatmentHealthy tissueIndividual variabilityOwn cellsTreatmentMedicineTherapeuticsDefense systemCurrent understandingCellsAutoantigens
2012
Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001
Barrett M, Lenkiewicz E, Evers L, Holley T, Aziz M, Kiefer J, Maitra A, Hidalgo M, Kumar R, Hlavacek W, Stites E, Posner R, Ramanathan R, Von Hoff D. Abstract 3697: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer - SU2C-001. Cancer Research 2012, 72: 3697-3697. DOI: 10.1158/1538-7445.am2012-3697.Peer-Reviewed Original ResearchComparative genomic hybridizationPhase II studyStudies of therapyMolecular profilingTreating metastatic pancreatic cancerK-rasPanel of xenograftsAneuploid tumour cell populationsMetastatic pancreatic cancerComparative genomic hybridization arrayAmerican Association for Cancer ResearchTherapeutic targetK-ras mutationsTumor cell populationGene expression microarray analysisExpression microarray analysisFocal ampliconsMetastatic lesionsMetastatic biopsiesC-kitGenomic hybridizationPancreatic cancerTumor nucleiHomozygous deletionDrug sensitivityAbstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium
Ramanathan R, Barrett M, Weiss G, Posner R, NV R, Jameson G, Demeure M, Hoering A, Stites E, Maitra A, Fulk M, Hidalgo M, Von Hoff D. Abstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium. Cancer Research 2012, 72: lb-221-lb-221. DOI: 10.1158/1538-7445.am2012-lb-221.Peer-Reviewed Original ResearchMetastatic pancreatic cancerPhase II studyMolecular profilingPercutaneous biopsyPerformance statusPancreatic cancerNon-cross-resistant regimenOutcome of salvage therapyPatients treated with FOLFIRIRefractory metastatic pancreatic cancerMetastatic pancreatic cancer patientsSurvival rateTreating metastatic pancreatic cancerAdequate bone marrowAdequate performance statusAneuploid tumour cell populationsYear survival rateAmerican Association for Cancer ResearchEfficacy of therapyFactors of patientsTumor cell populationLong-term survivalInsufficient tumorSalvage therapyStudies of therapy